Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab for COVID-19 Respiratory Symptoms
NCT04415073Phase 2Terminated
- Sponsor
- Syndax Pharmaceuticals
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in coronavirus disease 2019 (COVID-19), sponsored by Syndax Pharmaceuticals. Started May 2020; status: terminated.
02
Drugs
axatilimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04415073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415073.